Fig. 3

The expression of BCMA in plasma cell dyscrasias. A, B The bar diagrams showed the BCMA expression rate and BCMA MFI in patients with MM and NMM, respectively. The patients with MM had a significantly higher BCMA expression in both BCMA positive rate and BCMA MFI. The patients with MM had a median BCMA positive rate of 88.55% (range, 0.2% - 99.9%) and median BCMA MFI of 1281 (109 - 48586). While the median BCMA positive rate in NMM patients was 55.8% (6.2% -98.9%), and the median BCMA MFI was 553 (182- 5930). C, D There were no statistically significant differences between BCMA positive rate and BCMA MFI among patients with AL, POEMS syndrome, MGRS, and MGUS. The median BCMA expression rate in patients with AL, POEMS syndrome, MGRS, MGUS was 60.1% (6.2- 98.9%), 62.3% (35.5- 79.3%), 32.3% (22.8- 38.3%), 49.3% (8.6- 89.4%), respectively. The median BCMA MFI was 563 (182- 5930), 543 (325- 1656), 390 (243- 600), 614 (291- 1514), respectively. E, F There was no significant difference between the newly diagnosed and previously treated (post-therapy) patients with MM for both BCMA positive rate and MFI. The newly-diagnosed patients (n=244) with MM had a median BCMA positive rate of 86.55% (3.7- 99.9%), which was 87.9% (0.2- 99.9%) for the pre-treated (n=90) patients. The median BCMA MFI for the newly-diagnosed patients was 1235 (109- 19261) and 1431 (382- 48586) for the pre-treated patients. In the NMM group the median BCMA positive rate for the newly-diagnosed patients (n=38) was 47.4% (6.2 – 98.9%), and 93.8% (55.5 - 97.4%) for the pre-treated patients (n=5). The pre-treated patients had a higher BCMA expression rate than the newly-diagnosed patients, which may be due to the limited sample size of pre-treated patients. The median BCMA MFI for the newly-diagnosed patients were 538 (182 - 5930) and 998 (446 - 3897) for the pre-treated patients. There was no significant difference in BCMA MFI between newly diagnosed and pre-treated patients